Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 28.6% on Wednesday . The stock traded as high as C$0.14 and last traded at C$0.14. 421,375 shares traded hands during trading, an increase of 16% from the average session volume of 363,410 shares. The stock had previously closed at C$0.11.
Hemostemix Stock Up 20.0 %
The business’s 50 day simple moving average is C$0.09 and its 200 day simple moving average is C$0.07. The stock has a market cap of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- CD Calculator: Certificate of Deposit Calculator
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Trading Stocks: RSI and Why it’s Useful
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
-ltd-logo-1200x675.png?v=20241211120412&h=45&w=95&zc=2){kind=logo}
